Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 7, 2012, Pages 1170-1176

  Huang, Li Ping ^a   Yu, Yan Hong ^a   Sheng, Chao ^a   Wang, Sui Hai ^b  

^a FIRST MILITARY MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

CDH17; CDX2; Clinicopathology; Epithelial ovarian cancer; Prognosis

Indexed keywords

CADHERIN; CADHERIN 17; CARBOPLATIN; DOCETAXEL; PACLITAXEL; PARAFFIN; TRANSCRIPTION FACTOR CDX2; UNCLASSIFIED DRUG; CDH17 PROTEIN, HUMAN; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN;

ADULT; AGED; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL EVALUATION; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; UPREGULATION; ADENOCARCINOMA; ARTICLE; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; DISEASE COURSE; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; MORTALITY; OVARY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CADHERINS; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; SURVIVAL RATE;

EID: 84873251826     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318261d89c     Document Type: Conference Paper

References (30)

1. Annunziata CM, Stavnes HT, Kleinberg L, et al. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010;116:3276-3284.
2. Li YL, Ye F, Cheng XD, et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer. Eur J Cancer. 2010;46:2104-2118.
3. Chauhan SC, Singh AP, Ruiz F, et al. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol. 2006;19:1386-1394.
4. Angst BD, Marcozzi C, Magee AI. The cadherin superfamily: diversity in form and function. J Cell Sci. 2001;114:629-641.
5. Gessner R, Tauber R. Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci. 2000;915:136-143.
6. Lee HJ, Nam KT, Park HS, et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology. 2010;139:213-225.e3.
7. Zhang J, Liu QS, Dong WG. Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA. Med Oncol. 2011;28:494-501.
8. Liu QS, Zhang J, Liu M, et al. Lentiviral-mediated miRNA against liver-intestine cadherin suppresses tumor growth and invasiveness of human gastric cancer. Cancer Sci. 2010;101:1807-1812.
9. Wang XQ, Luk JM, Garcia-Barcelo M, et al. Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. Clin Cancer Res. 2006;12:5248-5252.
10. Yasui W, Oue N, Sentani K, et al. Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Pathol Int. 2009;59:121-136.
11. Suh YS, Lee HJ, Jung EJ, et al. The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer. Ann Surg Oncol. 2012;19:1240-1249.
12. Peleteiro B, Barros R, Carrilho C, et al. Determinants of gastric CDX2 expression: a study in Mozambique [published online ahead of print March 8, 2012]. Eur J Cancer Prev. doi: 10.1097/CEJ.0b013e3283523480.
13. Hinkel I, Duluc I, Martin E, et al. Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and A-catenin activity in colon cancer cells. Gastroenterology. 2012;142:875-885.e3.
14. Bonhomme C, Duluc I, Martin E, et al. The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut. 2003;52:1465-1471.
15. Renouf B, Soret C, Saandi T, et al. Cdx2 homeoprotein inhibits non-homologous end joining in colon cancer but not in leukemia cells. Nucleic Acids Res. 2012;40:3456-3469.
16. Peleteiro B, Lunet N, Wen X, et al. Association between environmental factors and CDX2 expression in gastric cancer patients. Eur J Cancer Prev. 2011.
17. Selamat SA, Galler JS, Joshi AD, et al. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. PLoS One. 2011;6:e21443.
18. Fraggetta F, Pelosi G, Cafici A, et al. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch. 2003;443:782-786.
19. Vang R, Gown AM, Wu LS, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19:1421-1428.
20. Gr?tzinger C, Kneifel J, Patschan D, et al. LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut. 2001;49:73-81.
21. Hinoi T, Lucas PC, Kuick R, et al. CDX2 regulates liver intestine-cadherin expression in normal and malignant colon epithelium and intestinal metaplasia. Gastroenterology. 2002;123:1565-1577.
22. Ko S, Chu KM, Luk JM, et al. CDX2 co-localizes with liver-intestine cadherin in intestinal metaplasia and adenocarcinoma of the stomach. J Pathol. 2005;205:615-622.
23. Ito R, Oue N, Yoshida K, et al. Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer. Virchows Arch. 2005;447:717-722.
24. Ge J, Chen Z, Wu S, et al. A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma. Clin Oncol (R Coll Radiol). 2008;20:275-283.
25. Zhu R, Wong KF, Lee NP, et al. HNF1α and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem. 2010;111:618-626.
26. Kim HJ, Jeon HK, Cho YJ, et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 2012.
27. Lee NP, Poon RT, Shek FH, et al. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta. 2010;1806:138-145.
28. Su MC, Yuan RH, Lin CY, et al. Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol. 2008;21:1379-1386.
29. Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin-17 on lymph node micrometastasis in pN0 gastric cancer. Ann Surg Oncol. 2012;19:1529-1534.
30. Takamura M, Sakamoto M, Ino Y, et al. Expression of liver-intestine cadherin and its possible interaction with galectin-3 in ductal adenocarcinoma of the pancreas. Cancer Sci. 2003;94:425-430.